Endonovo Therapeutics, Inc. (ENDV) financial statements (2022 and earlier)

Company profile

Business Address 6320 CANOGA AVENUE
WOODLAND HILLS, CA 91367
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 1319379905641
Cash and cash equivalents 1319379905641
Receivables 1233   
Other current assets      3
Other undisclosed current assets 3221 21247 
Total current assets: 466338211130344
Noncurrent Assets
Property, plant and equipment 26711632
Intangible assets, net (including goodwill) 2,5593,2063,8534,500  
Intangible assets, net (excluding goodwill) 2,5593,2063,8534,500  
Total noncurrent assets: 2,5613,2123,8604,5011632
TOTAL ASSETS: 2,6073,2754,2424,61231976
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 2,6051,9179432,7144,7383,990
Accounts payable 701599157   
Accrued liabilities   786   
Interest and dividends payable 1,9041,317    
Other undisclosed accounts payable and accrued liabilities    2,7144,7383,990
Debt 6,4916,6976,05441212
Deferred compensation liability 3,3842,4312,246   
Derivative instruments and hedges, liabilities 4,20310,6004,4265,9401,9281,970
Due to related parties 1431652702067
Other undisclosed current liabilities  1,8131,5394,7312,0371,504
Total current liabilities: 16,82623,62315,47913,4098,7217,483
Noncurrent Liabilities
Long-term debt and lease obligation  383222417
Long-term debt, excluding current maturities  383222417
Other undisclosed noncurrent liabilities 155117123731155166
Total noncurrent liabilities: 155155155753159183
Total liabilities: 16,98123,77815,63414,1638,8817,665
Temporary equity, carrying amount  1,8131,539598  
Stockholders' equity
Stockholders' equity attributable to parent, including: (14,374)(20,504)(11,392)(9,550)(8,562)(7,589)
Preferred stock 0000  
Common stock 2043321310
Common stock, share subscribed but unissued, subscriptions receivable (2)(2)(2)   
Common stock, value, subscriptions    (2)(2)(2)
Additional paid in capital 38,96432,43224,18719,6049,8013,774
Accumulated deficit (53,339)(52,935)(35,620)(29,184)(18,374)(11,372)
Other undisclosed stockholders' equity attributable to parent 000   
Other undisclosed stockholders' equity  (1,813)(1,539)(598)  
Total stockholders' equity: (14,374)(22,317)(12,931)(10,148)(8,562)(7,589)
TOTAL LIABILITIES AND EQUITY: 2,6073,2754,2424,61231976

Income statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 16631083  4
Revenue, net  4
Cost of revenue (65)(93)(13)  (2)
Cost of goods and services sold      (2)
Gross profit: 10021770  2
Operating expenses (3,013)(4,026)(4,230)(4,604)(5,411)(2,500)
Operating loss: (2,912)(3,809)(4,159)(4,604)(5,411)(2,498)
Nonoperating income (expense) 2,517(13,505)(2,277)(6,206)95(2,581)
Other nonoperating income (expense) (452)(13,505)(2,277)(6,206)95(2,581)
Interest and debt expense (555)(17)3172,485(488)(128)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes  17(317)(2,485)488128
Loss from continuing operations before equity method investments, income taxes: (951)(17,315)(6,436)(10,810)(5,316)(5,079)
Other undisclosed income from continuing operations before income taxes 555     
Net loss available to common stockholders, diluted: (396)(17,315)(6,436)(10,810)(5,316)(5,079)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (396)(17,315)(6,436)(10,810)(5,316)(5,079)
Comprehensive loss, net of tax, attributable to parent: (396)(17,315)(6,436)(10,810)(5,316)(5,079)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: